About Biosensia
Biosensia is a company based in Dublin (Ireland) founded in 2006 was acquired by Kypha in July 2018.. Biosensia has raised $4.58 million across 3 funding rounds from investors including Enterprise Ireland, Kypha and Street Capital. Biosensia offers products and services including RAPIPLEX™, COMP ACT ®, and Custom Panel Development. Biosensia operates in a competitive market with competitors including Abingdon Health, Olink, US BioTek Laboratories, Spear Bio and Eclipse Bio, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.58 M (USD)
in 3 rounds
-
Latest Funding Round
$730.29 K (USD), Grant
Jul 01, 2015
-
Investors
Enterprise Ireland
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Kypha
(Jul 15, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosensia
Biosensia offers a comprehensive portfolio of products and services, including RAPIPLEX™, COMP ACT ®, and Custom Panel Development. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides simultaneous quantitative analysis of up to 24 proteins from samples.
Enables quantitative testing with minimal sample volume for immune insights.
Creates tailored panels for specific biomarker needs in research.
Funding Insights of Biosensia
Biosensia has successfully raised a total of $4.58M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $730.29 thousand completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $730,292
-
First Round
First Round
(05 Feb 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2015 | Amount | Grant - Biosensia | Valuation |
investors |
|
| Nov, 2011 | Amount | Series A - Biosensia | Valuation | Act Venture Capital | |
| Feb, 2008 | Amount | Series A - Biosensia | Valuation | Seroba Life Sciences |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biosensia
Biosensia has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Enterprise Ireland, Kypha and Street Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Atlantic Bridge is focused on growth equity investments in technology.
|
Founded Year | Domain | Location | |
|
Early-stage venture capital funding is provided to innovative companies.
|
Founded Year | Domain | Location | |
|
Seroba Lifesciences is focused on life sciences venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biosensia
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biosensia
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biosensia Comparisons
Competitors of Biosensia
Biosensia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Olink, US BioTek Laboratories, Spear Bio and Eclipse Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
Provider of products and services for human protein biomarker research and development
|
|
| domain | founded_year | HQ Location |
Provider of enzyme-linked immunosorbent assay technology services
|
|
| domain | founded_year | HQ Location |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| domain | founded_year | HQ Location |
Cell-free immunoassays are developed to identify RNA binding protein targets.
|
|
| domain | founded_year | HQ Location |
An in vitro assay platform is provided for diagnostic solutions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Biosensia
When was Biosensia founded?
Biosensia was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Where is Biosensia located?
Biosensia is headquartered in Dublin, Ireland.
Is Biosensia a funded company?
Biosensia is a funded company, having raised a total of $4.58M across 3 funding rounds to date. The company's 1st funding round was a Series A of $2.93M, raised on Feb 05, 2008.
What does Biosensia do?
Biosensia was founded in 2006 in Dublin, Ireland, and operates in the medtech sector focused on in vitro diagnostics. A platform called RapiPlex is being developed, which includes a disposable assay cartridge and a compact tabletop instrument. Immunoassays can be performed at a doctors office or patients bedside using samples such as whole blood, serum, saliva, urine, or swabs. The system is currently approved for research use only.
Who are the top competitors of Biosensia?
Biosensia's top competitors include Abingdon Health, SurModics and Eclipse Bio.
What products or services does Biosensia offer?
Biosensia offers RAPIPLEX™, COMP ACT ®, and Custom Panel Development.
Who are Biosensia's investors?
Biosensia has 7 investors. Key investors include Enterprise Ireland, Kypha, Street Capital, Atlantic Bridge, and Seroba Lifesciences.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.